A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion.
Burtness B, Belker M, Stoltz M, Peccerillo KM, Lamb LA, Chmael SE, McKeon A, Clark MB, Winship J, Marsh JC, Pizzorno G, DeVita VT Jr.
Cancer J. 2000 Sep-Oct;6(5):309-15.PMID: 11079170 [PubMed - indexed for MEDLINE]Related articles